Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.7%

2 terminated/withdrawn out of 115 trials

Success Rate

88.2%

+1.7% vs industry average

Late-Stage Pipeline

15%

17 trials in Phase 3/4

Results Transparency

1 of 15 completed trials have results

Key Signals

24 recruiting1 with results

Enrollment Performance

Analytics

N/A

34(43.6%)

Phase 2

21(26.9%)

Phase 4

11(14.1%)

Phase 3

6(7.7%)

Early Phase 1

3(3.8%)

Phase 1

3(3.8%)

78Total

N/A(34)

Phase 2(21)

Phase 4(11)

Phase 3(6)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (115)

Showing 20 of 115 trials

NCT07533825Not ApplicableEnrolling By Invitation

Laparoscopic Staging for Stage III Gastric Cancer

Role: collaborator

NCT04801004Completed

A Real-world Study to Evaluate the Primary Patency and Freedom From TLR of Endovascular Treatment in TOSAKA III In-stent Restenosis of Lower Extremity Femoropopliteal Artery.

Role: collaborator

NCT06319118Phase 4Completed

A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease.

Role: lead

NCT07481929Completed

Predictors of Fracture-Dislocation in Schatzker IV Tibial Plateau Fractures: A Reproducible, Quantitative MRI-Based Injury-Pattern Analysis

Role: lead

NCT06265051Phase 2Completed

Tirofiban After Successful MT Recanalization in AIS

Role: collaborator

NCT05387031Recruiting

Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease

Role: collaborator

NCT05537597Not ApplicableCompleted

Repetitive Transcranial Magnetic Stimulation for Musculoskeletal Pain in Patients With Parkinson's Disease

Role: lead

NCT07176091Not ApplicableEnrolling By Invitation

Clinical Efficacy of Intermittent Theta Burst Transcranial Magnetic Stimulation With Different Modes on Parkinson's Disease

Role: lead

NCT07258160Phase 2Recruiting

Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors

Role: lead

NCT07327411Phase 2Not Yet Recruiting

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Role: lead

NCT07323381Phase 4Not Yet Recruiting

Effects of Henagliflozin Proline and Metformin XR on Body Composition in Geriatric Patients With Newly Diagnosed T2DM

Role: collaborator

NCT04943913Early Phase 1Recruiting

Study of GC101 TIL in Brain Glioma (Soochow2)

Role: collaborator

NCT07267234Phase 2Not Yet Recruiting

PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)

Role: lead

NCT04534023Phase 2Active Not Recruiting

A Clinical Study of the Efficacy of Idebenone in the Treatment of iRBD Into Synucleinopathies

Role: collaborator

NCT07241897Phase 3Not Yet Recruiting

DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes

Role: lead

NCT07231523Phase 3Not Yet Recruiting

EFG vs IVIG in TAMG

Role: collaborator

NCT07230574Phase 2Not Yet Recruiting

Autologous Decidual-like Natural Killer Cells Therapy for Reproductive Failure

Role: collaborator

NCT07200388Not Yet Recruiting

How Emotional Granularity Helps Build Resilience in Young and Middle-Aged Colorectal Cancer Survivors

Role: collaborator

NCT07196982Completed

Risk Factors for Intertrochanteric Femoral Fractures With Concomitant Lateral Wall Involvement in Elderly Women

Role: lead

NCT07153744Phase 4Not Yet Recruiting

Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction

Role: collaborator